Regression of vasoproliferative tumor with systemic infliximab.
The anti-tumor necrosis factor (TNF) monoclonal antibody infliximab inhibits the pleiotropic actions of TNF and is widely used for the treatment of inflammatory diseases, such as uveitis. A pathogenetic role of TNF in ocular inflammatory conditions has recently emerged. The authors describe a patient with collagen mixed disease who had decreased vision in the left eye. Fundus examination disclosed bilateral peripheral vasoproliferative tumors and macular edema in the left eye. The patient underwent treatment with infliximab intravenously for his systemic condition. Regression of the vasoproliferative tumors in both eyes and improvement of macular edema in the left eye was observed. Although the data are limited, anti-TNF antibodies such as infliximab may be useful in the treatment of retinal vascular tumors.
Japiassú
Ricardo M
RM
Pedro Ernesto University Hospital, State University of Rio de Janeiro, Rio de Janeiro, Brazil.
Brasil
Oswaldo F Moura
OF
Cunha
Aníbal L
AL
de Souza
Eduardo C
EC
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006391:Hemangioma / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D008269:Macular Edema / Q000188:drug therapy; D008297:Male; D012163:Retinal Detachment / Q000188:drug therapy; D019572:Retinal Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab